Business Context and Reporting Period
This Form 8-K is a current report filed by Aeglea Biotherapeutics, Inc. (not Spyre Therapeutics, Inc.) on December 17, 2020, regarding events occurring on December 15, 2020. The company is a Delaware corporation with its principal executive offices in Austin, Texas, and its common stock trades on the Nasdaq Global Market under the symbol "AGLE". The filing identifies the registrant as an emerging growth company.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on corporate governance and director compensation.
Material Changes
The primary material change reported is the appointment of Alison Lawton as a Class I director and chair of the Nominating and Governance Committee, effective December 15, 2020. No changes to financial operations or strategic direction are disclosed in this report.
Guidance, Outlook, and Compensation Details
Management commentary is limited to the details of the new director's appointment and compensation package:
- Annual Retainer: Ms. Lawton will receive a pro rata portion of the $40,000 annual retainer for director service and a pro rata portion of the $8,000 annual retainer for chairing the Nominating and Governance Committee.
- Stock Option Grant: The Board granted an option to purchase 47,200 shares of common stock. The exercise price is set at the closing sale price on December 15, 2020. The option vests monthly over three years, contingent on continued service.
- Indemnification: A standard indemnification agreement was executed, previously filed as Exhibit 10.1 to the Company's Form S-1.
The filing states there are no family relationships between Ms. Lawton and other directors or officers, and no undisclosed arrangements regarding her selection.
Investor Verification Checklist
- Verify the correct registrant name is Aeglea Biotherapeutics, Inc., as the input metadata incorrectly referenced Spyre Therapeutics, Inc.
- Confirm the vesting schedule and exercise price of the 47,200 share option grant for Alison Lawton.
- Review the Company's existing compensation policy for non-employee directors to validate the pro rata retainer calculations.
- Note that this filing contains no financial results; refer to the most recent 10-Q or 10-K for financial metrics.